Literature DB >> 1728060

Modification of intracellular pH and thermosensitivity.

J C Lyons1, G E Kim, C W Song.   

Abstract

The effects of amiloride (an inhibitor of Na+/H+ antiport), DIDS (an inhibitor of Na(+)-coupled and Na(+)-independent HCO3-/Cl- exchange) and nigericin (K+/H+ ionophore) alone and in various combinations on the intracellular pH (pHi) and thermosensitivity of SCK tumor cells were studied. Hyperthermia alone at 43 degrees C for 2 h decreased pHi of SCK cells by 0.15-0.20 pH units, as measured fluorometrically using the pH-sensitive dye BCECF. When the cells were treated with 0.5 mM amiloride at 37 degrees C, the pHi declined by 0.10-0.15 pH units at an extracellular pH (pHe) of both 7.2 and 6.6. Amiloride at 0.5 mM enhanced the thermal damage to SCK cells at pHe 6.6 but not at pHe 7.2. DIDS alone at 0.1 mM exerted no effect on pHi or cellular thermosensitivity. DIDS, however, enhanced the effects of amiloride in decreasing pHi and in increasing the thermoresponse of SCK cells, particularly at pHe 6.6. Treatment of the cells with nigericin at 0.1-1.0 micrograms/ml lowered the pHi and enhanced the thermosensitivity of the cells in a dose-dependent manner. Reductions in pHi and increases in thermosensitivity by nigericin at the lower concentration at pHe 6.6 were far greater than at pHe 7.2. When a mixture of 1.0 micrograms/ml nigericin, 0.5 mM amiloride, and 0.1 mM DIDS was present in the medium, the pHi rapidly decreased by about 0.3 and 0.4 pH units at pHe 7.2 and 6.6, respectively. This drug combination was also extremely effective in sensitizing SCK cells to heat, particularly at pHe 6.6. The fact that the thermosensitization by these drugs at pHe 6.6 is more pronounced than at pHe 7.2 and that intratumor environments are known to be acidic strongly suggested that it may then be possible to enhance the thermal damage with such drugs preferentially in tumors relative to normal tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728060

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  8 in total

1.  Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.

Authors:  O Ben-Yoseph; J C Lyons; C W Song; B D Ross
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

Review 2.  Manipulating extracellular tumour pH: an effective target for cancer therapy.

Authors:  Guanyu Hao; Zhi Ping Xu; Li Li
Journal:  RSC Adv       Date:  2018-06-19       Impact factor: 4.036

Review 3.  Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia.

Authors:  M Busse; P Vaupel
Journal:  Experientia       Date:  1996-05-15

Review 4.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

5.  (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Authors:  Kavindra Nath; David S Nelson; Andrew M Ho; Seung-Cheol Lee; Moses M Darpolor; Stephen Pickup; Rong Zhou; Daniel F Heitjan; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2012-06-29       Impact factor: 4.044

6.  Topiramate induces acute intracellular acidification in glioblastoma.

Authors:  Kamini Marathe; Nevin McVicar; Alex Li; Miranda Bellyou; Susan Meakin; Robert Bartha
Journal:  J Neurooncol       Date:  2016-09-09       Impact factor: 4.130

7.  Rapid increase in pH set-point of the Na(+)-in-dependent chloride/bicarbonate antiporter in Vero cells exposed to heat shock.

Authors:  J Ludt; K Sandvig; S Olsnes
Journal:  J Membr Biol       Date:  1993-06       Impact factor: 1.843

8.  Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours.

Authors:  M J Boyer; M Barnard; D W Hedley; I F Tannock
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.